Oncologists explain why ALK+ NSCLC patients switch therapies

Download the Report: Discover the Drivers of Treatment Discontinuation and Switching in ALK+ NSCLC Patients

Competition will only grow in the ALK+ NSCLC treatment landscape as emerging therapies join current drug options. Standing out in this limited patient population will be more important than ever before.

OptimizeRx surveyed oncologists across the U.S. to find out:

Which ALK+ NSCLC treatments are most highly ranked on a variety of key attributes

How oncologists educate patients about their prescribed treatment,
financial assistance options and
patient support programs

Why at least 25% of patients with ALK+ NSCLC discontinue or switch treatment

Download the report today and discover new opportunities in the crowded ALK+ NSCLC market.

Download the Report:Discover the Drivers of TreatmentDiscontinuation and Switching in ALK+ NSCLC Patients